Dr. William J. Polvino, MD
Dr. Polvino joined Veloxis in September 2009, bringing extensive experience in the senior management of pharmaceutical companies and solid operational experience in drug development and specialty pharma strategy. Earlier in his career, Dr. Polvino was CEO at Helsinn Therapeutics US, Inc (a private company), formerly Sapphire Therapeutics. At Sapphire, he helped drive novel in-licensed new chemical entities into late-stage clinical development, successfully leading the company through acquisition to Helsinn Therapeutics US in January 2009.
Dr. Polvino began his career in the life science industry following his professional training in Internal Medicine at Massachusetts General Hospital and his fellowship in Clinical Pharmacology at the National Institute of Health, USA.
Dr. Polvino has held various senior positions of increasing responsibility within drug development and executive functions at Merck, Wyeth, and Theravance prior to joining Sapphire Therapeutics in 2002. Dr. Polvino holds six issued US patents and corresponding international counterparts.
Mr. Stilou joined Veloxis in April 2008. He is responsible for the activities within Finance, IT, Legal Affairs, and Investor Relations.
Dr. John Weinberg, MD
Dr. Weinberg joined Veloxis in July 2010. He is responsible for managing all commercial activities supporting the Veloxis portfolio of compounds in development. Additionally, Dr. Weinberg directs Corporate Strategy and Pipeline Target Identification.
Ms. Sylvest joined Veloxis in April 2008. She is responsible for clinical development, clinical operations, and drug supply.
Mr. Breian Knudsen
Mr. Knudsen joined Veloxis in November 2007. He is responsible for technology transfer, process validation, and clinical and commercial manufacturing.
Mr. Knudsen has extensive experience within process and product development, technology transfer, process validation, and manufacture within the pharmaceutical industry.
Prior to joining Veloxis, Mr. Knudsen held a position as Principal Scientist, Chemistry Manufacturing & Controls (CMC) project manager at Novo Nordisk A/S, where he headed the CMC part of a number of solid dosage development projects and where he implemented guidelines for systematic in-house and external transfer of manufacturing processes.
Mr. Knudsen holds an MSc degree in Pharmacy from the Pharmaceutical University of Copenhagen.
Ron Guido has been employed in pharmaceutical development since 1980, in the areas of preclinical screening, clinical research, regulatory affairs, product development, and quality systems. Experience includes development strategy, merger and acquisition, as well as commercial support for new and marketed products. Past positions include Vice-President Regulatory, Retrophin, Inc; Senior Director and Therapeutic Area Head for Cardiovascular Medicine – Worldwide Regulatory Strategy for Pfizer, as well as senior roles with V.I. Technologies/ Precision Pharma Services, Whitehall-Robins Healthcare, Fresenius Pharma USA, and Wyeth-Ayerst Laboratories.
Mar 9, 2016
Release of Annual Report 2015
Mar 9, 2016
Offentliggørelse af årsrapport for 2015
Apr 6, 2016
Apr 6, 2016
Annual General Meeting